US 11,730,746 B2
17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure
Alberto Cerri, Milan (IT); Giuseppe Bianchi, Milan (IT); Patrizia Ferrari, Varese (IT); Mara Ferrandi, Milan (IT); Paolo Barassi, Castelvaccana (IT); Antonio Zaza, Milan (IT); Marcella Rocchetti, Brugherio (IT); Carlotta Ronchi, Milan (IT); and Shih-Che Hsu, Taipei (TW)
Assigned to CVie Therapeutics Limited, Taipei (TW)
Appl. No. 17/263,209
Filed by CVie Therapeutics Limited, Taipei (TW)
PCT Filed Jul. 17, 2019, PCT No. PCT/EP2019/069283
§ 371(c)(1), (2) Date Jan. 26, 2021,
PCT Pub. No. WO2020/020728, PCT Pub. Date Jan. 30, 2020.
Claims priority of application No. 18185753 (EP), filed on Jul. 26, 2018.
Prior Publication US 2021/0283147 A1, Sep. 16, 2021
Int. Cl. A61K 31/58 (2006.01); A61P 9/04 (2006.01); A61K 31/04 (2006.01); A61K 31/138 (2006.01); A61K 31/196 (2006.01); A61K 31/216 (2006.01); A61K 31/277 (2006.01); A61K 31/34 (2006.01); A61K 31/341 (2006.01); A61K 31/4035 (2006.01); A61K 31/404 (2006.01); A61K 31/41 (2006.01); A61K 31/4178 (2006.01); A61K 31/4184 (2006.01); A61K 31/4422 (2006.01); A61K 31/496 (2006.01); A61K 31/50 (2006.01); A61K 31/517 (2006.01); A61K 31/549 (2006.01); A61K 31/554 (2006.01); A61K 31/585 (2006.01); A61K 31/64 (2006.01); A61K 31/7048 (2006.01); A61K 38/06 (2006.01); A61K 38/22 (2006.01); A61K 45/06 (2006.01); C07J 43/00 (2006.01)
CPC A61K 31/58 (2013.01) [A61K 31/04 (2013.01); A61K 31/138 (2013.01); A61K 31/196 (2013.01); A61K 31/216 (2013.01); A61K 31/277 (2013.01); A61K 31/34 (2013.01); A61K 31/341 (2013.01); A61K 31/404 (2013.01); A61K 31/4035 (2013.01); A61K 31/41 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/4422 (2013.01); A61K 31/496 (2013.01); A61K 31/50 (2013.01); A61K 31/517 (2013.01); A61K 31/549 (2013.01); A61K 31/554 (2013.01); A61K 31/585 (2013.01); A61K 31/64 (2013.01); A61K 31/7048 (2013.01); A61K 38/06 (2013.01); A61K 38/2221 (2013.01); A61K 38/2242 (2013.01); A61K 45/06 (2013.01); A61P 9/04 (2018.01); C07J 43/003 (2013.01)] 20 Claims
 
1. Compounds of formula (I)

OG Complex Work Unit Chemistry
wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; and wherein:
n is 0 or 1 and said heterocyclic ring selected from the group consisting of imidazolyl, pyrazolyl, thiazolyl, isoxazolyl, and the corresponding dihydro- and tetrahydro derivatives;
R is H or OH; and
the dotted line represents an optional double bond C=C; the thick line represents a bond in the β configuration; the wavy line represents a bond both in the α and β configuration; or
the pharmaceutically acceptable salts, solvates, or hydrates thereof.